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Aims. Proteinuria not only is a sign of kidney damage, but also is involved in the progression of renal diseases as an independent
pathologic factor. Clinically, glomerular proteinuria is most commonly observed, which relates to structural and functional
anomalies in the glomerular ﬁltration barrier. The aim of this paper was to describe the pathogenesis of glomerular proteinuria.
Data Sources. Articles on glomerular proteinuria retrieved from Pubmed and MEDLINE in the recent 5 years were reviewed.
Results. The new understanding of the roles of glomerular endothelial cells and the glomerular basement membrane (GBM) in the
pathogenesis of glomerular proteinuria was gained. The close relationships of slit diaphragm (SD) molecules such as nephrin,
podocin, CD2-associated protein (CD2AP), a-actinin-4, transient receptor potential cation channel 6 (TRPC6), Densin and
membrane-associated guanylate kinase inverted 1 (MAGI-1), α3β1 integrin, WT1, phospholipase C epsilon-1 (PLCE1), Lmx1b,
and MYH9, and mitochondrial disorders and circulating factors in the pathogenesis of glomerular proteinuria were also gradually
discovered. Conclusion. Renal proteinuria is a manifestation of glomerular ﬁltration barrier dysfunction. Not only glomerular
endothelial cells and GBM, but also the glomerular podocytes and their SDs play an important role in the pathogenesis of
glomerular proteinuria.
1.Introduction
Under normal conditions, high molecular weight proteins in
the plasma (e.g., albumin and globulin) cannot pass through
the ﬁltration membrane due to the eﬀects of the size barrier
and charge barrier of the glomerular capillary ﬁltration
membrane. Low molecular weight proteins (e.g., β2-micro-
globulin (β2-M), α1-microglobulin (α1-M), and lysozyme),
however, can freely pass through the ﬁltration membrane,
although the ﬁltration amount is low and 95% of these pro-
teins are reabsorbed when entering the proximal convoluted
tubule. The ﬁnal urine protein content is therefore low (only
30–130mg/24h) and consists primarily of plasma albumin
(40%), immunoglobulin fragments (15%), other plasma
proteins (5%), and urinary system-originating tissue pro-
teins (40%). The protein concentration in a random urine
sample is 0–80mg/L, and the results of qualitative tests for
urokinase protein are typically negative. When the urine
protein exceeds 150mg/24h or the concentration is above
100mg/L, the result for the qualitative protein test becomes
positive. This is known as proteinuria [1, 2].
Proteinuria is the most common manifestation of renal
diseases. Reviews of a number of experimental studies have
shown that proteinuria is not only a sign of kidney damage,
but also participates in the progression of renal diseases as an
independent pathologic factor [3–5]. Clinically, glomerular
proteinuria is most commonly observed and relates to struc-
tural and functional anomalies in the glomerular ﬁltration
barrier. In recent years, researchers have not only gained a
new understanding of the roles of glomerular endothelial
cells and the glomerular basement membrane (GBM) in the
pathogenesis of proteinuria, but have also gradually discov-
ered the close relationships of slit diaphragm (SD) molecules
such as nephrin, podocin, CD2-associated protein (CD2AP),
a-actinin-4, transient receptor potential cation channel
6 (TRPC6), Densin, and membrane-associated guanylate
kinase inverted 1 (MAGI-1) in the pathogenesis of protein-
uria. In this paper, research progress in the pathogenesis of
glomerular proteinuria in recent years is reviewed.2 International Journal of Nephrology
2. The Structure of the Glomerular
Filtration Barrier
The glomerular ﬁltration barrier is comprised of three layers.
(1) Capillary endothelial cells in the inner layer. A variety of
fenestrae, small ostioles of 50–100nm in diameter on endo-
thelial cells, may prevent hematocytes from passing through.
These fenestrae may not intercept plasma proteins to be
ﬁltrated, but the negative proteoglycans on their surface may
e x e r ts o m ec h a r g eb a r r i e re ﬀect. (2) The cellular basement
membrane in the interface layer. This is the major ﬁltration
barrier of the ﬁltration membrane, is approximately 100nm
thick, and consists of the inner and outer loose tectoria
and the intermediate stratum compactum. The GBM is a
microﬁbrous reticulum structure composed of hydrated gel
thatexertsitscharge-barrierandsize-barrierfunctionsviaits
rich surface anion charges and ﬁbrous strap meshwork-like
aperture screen stencil. (3) The visceral epithelial cells in
the outer layer. Epithelial cells have podocytic processes that
form ﬁssures among them through reciprocal overlapping.
There is a layer of ﬁltration ﬁssure membrane on the ﬁssures
with holes of 4–14nm in diameter on its surface that
represent the last barrier of the ﬁltration membrane. Under
normal circumstances, the radius of an eﬀective ﬁltration
hole in the glomerular ﬁltration membrane is approximately
30 angstroms. Small molecular proteins such as lysozyme
and β2-microglobulin can be ﬁltered, while proteins with
molecular weights above 60,000–70,000 are diﬃcult to ﬁlter.
The molecular weight of plasma albumin is 69,000, and the
molecular radius is approximately 37 angstroms, making it
diﬃcult to pass through the ﬁltration membrane. Patho-
logically, as a result of antibasement membrane antibody
and immune complex deposition, as well as the release of
cytokines and inﬂammatory mediators, glomerular capillary
damage may occur with increased permeability. This allows
a large number of plasma proteins, especially albumins in
the Bowman’s capsule, to exceed the proximal renal tubule’s
ability to reabsorb proteins and induce proteinuria.
3.GlomerularEndothelial Cells
andProteinuria
The diﬀerence between glomerular endothelial cells and
other vascular endothelial cells lies in their ﬂatter surfaces
and fenestrae that are approximately 50–100nm in diameter.
Glomerular endothelial cells are the ﬁrst line of defense of
the glomerular ﬁltration barrier. The ﬁbrils, which are 7nm
thick and exist inside the endothelial cytoplasm, constitute
the fenestrate structure. Changes in the aperture of ﬁbrils
mayaﬀectvesselwallpermeability.Endothelialcellstructural
proteins (e.g., actin, myoglobulin) may also aﬀect the diame-
ter of the fenestrate structure via growth factors. In addition,
synergism between the inherent special structures (such as
cell membrane-like depression, zonula occludens, and
glycocalyx) of glomerular endothelial cells and circulatory
permeabilityfactors(suchasa-acidicmucin,apolipoprotein,
and Amadori’s product) may generate the endothelial
cell-GBM-podocyte axis, thus playing a special role in
maintaining the integrity of the ﬁltration barrier [6, 7].
The cell coat on the surface of glomerular endothelial
cells, also known as glycocalyx, is approximately 300nm
thick. It consists of proteoglycan, glycosaminoglycan, and
plasma proteins such as orosomucoids that are rich in neg-
ative charges. Plasma proteins can be secreted by endothelial
cells and are closely related to the permeability of glomerular
capillaries. Glycocalyx can aﬀect blood ﬂow velocity and
exertaselectivebarriereﬀectonmacromolecularmovement.
Damage to systemic endothelial glycocalyx is associated with
the onset of albuminuria in patients with type 1 diabetes [8].
Glycocalyx is perturbed in individuals with type 2 diabetes,
and oral glycocalyx precursor treatment improves glycocalyx
properties [9]. Recently, it has been reported that damage to
the endothelial glycocalyx alters the permeability of multiple
capillary beds: in the glomerulus this is clinically apparent
as albuminuria [10]. It has been found in endothelial cells
cultured in vitro that the glycosaminoglycan hyaluronan in
glycocalyx may generate a matrix with molecular sieve prop-
erties in order to maintain the charge barrier [11, 12].
In addition, orosomucoid plays an important role in main-
taining the charge barrier by interacting with the glycocalyx
of endothelial cells [6, 13].
4. GBM andProteinuria
Like the basement membranes of other structures of the
human body, the GBM is a microﬁbrous reticular structure
primarily consisting of collagen type IV, laminin (primarily
laminin-11 and α5β2γ11), nidogen (entactin/nidogen), and
heparan sulfate (primarily perlecan and agrin). It is a layer
of acellular basement membrane that is 300–350nm in
thickness and plays a role in glomerular ﬁltration as well
as podocyte adhesion, migration, and diﬀerentiation. Such a
molecular structure endows the GBM with the dual func-
tions of being the mechanical barrier and charge barrier, and
abnormalities in each role may lead to proteinuria.
4.1. Collagen Type IV and Proteinuria. Collagen type IV is a
triple helix protein composed of three α chains. Its molecular
weight is 180kDa, and it consists of isomeric chains (α1–α6)
encoded by six diﬀerent genes. These genes form the reti-
cular structure via intermolecular interactions, shaping the
fundamental skeleton of the GBM; other molecules attach to
it in diﬀerent ways. During human fetation, collagen type IV
is dominated by α1.α1.α2 tripolymer-originating meshwork
in the earliest stage of forming the GBM vascular loop;
however, with the gradual development and maturity of
the glomerular capillary loop, collagen type IV is gradually
replaced by α3.α4.α5 tripolymer-originating meshwork. The
alteration in collagen type IV during fetation is thought to
be related to oxidative and physical stress. In the kidneys,
since plasma proteins contain a variety of proteases that
contact the GBM directly and the α3.α4.α5t r i p o l y m e ri s
rich in disulﬁde bonds, the α1.α1.α2t r i p o l y m e rm a yb e
more resistant to the eﬀects of proteases and various
physical stimuli. When gene mutations occur in the α1-α5
chain,theGBMdevelops irregularpachynsis,multiplestrati-
ﬁcations, and a reticular structure. This is manifested as
hereditary nephropathy-Alport syndrome, which is clinicallyInternational Journal of Nephrology 3
characterized by progressive hematuria, proteinuria, and
renal failure. If the gene encoding α4 chain is mutated, “thin
basement membrane disease” can occur, which is character-
ized by hematuria under the microscope and is also known
as “benign familial hematuria.” When autologous antibodies
are present in the NCI structural region of the anticollagen
type IV α3 chain, the GBM mechanical barrier is disrupted
and produces massive proteinuria. This is clinically referred
to as “Goodpasture syndrome” [14–16].
4.2. Laminin and Proteinuria. Laminin, secondary only to
collagen in GBM content, is a heterotrimeric glycosidopro-
tein composed of α, β,a n dγ chains. It is cross-shaped
and provides the supporting structure for other parts of the
GBM. It is believed that there are ﬁve α chains, three β chains
and two γ chains in humans, forming 11 diﬀerent types of
laminintripolymer.MutationsintheLAMB2gene,encoding
the laminin β2 chain, are associated with the Pierson’s syn-
drome.ThehumanLAMB2genemapstochromosomeband
3p21 and is composed of 32 densely packed exons spanning
about 12kb of genomic DNA [17]. Mutations in the LAMB2
were also found in patients with congenital nephrotic syn-
drome [18], and LAMB2 mutations were reported to result
in loss of laminin-β2 expression in the kidney [19]. LAMB2
knockout mice, which model is Pierson syndrome, show
congenital albuminuria followed by podocyte foot process
eﬀacement, and they die at about 3 weeks of age with severe
neuromuscular defects and nephrotic syndrome [20]. A
recent case reported a minor variant of Pierson syndrome in
a teenage girl with severe myopia since early infancy and
proteinuria ﬁrst detected at age 6. At the age of 11 she was
found to carry a unique homozygous nontruncating LAMB2
mutation [21].
Similar to collagen type IV, during the development of
the kidney, a series of changes occur to the upper laminin
layer of the GBM, from laminin-10 (α5β1γ1) in the fetal
period to laminin-11 (α5β2γ1) in the mature period. Lam-
inin-11, which contains β2, is a glycosidoprotein that is
indispensable for maintaining the function of the GBM.
Although β2 knockout mice have an intact GBM ultra-
structure, when GBM functions are severely damaged, the
mice develop massive proteinuria seven days following birth
and extensive pathologically fusion of glomerular podocytic
processes occur, similar to the minute lesions in human
beings. In addition, the emergence of proteinuria occurs in
advance of subpodocytic fusion and SD disappearance, and
themicedie3–5weeksafterbirth.Thisindicatesthatlaminin
may play an important role in cell-matrix interaction [22].
Laminin interacts with the various components of the GBM
such as agrin, nidogen, and perlecan and is associated with
cell surface receptors such as integrin α3β1, α6β1a n dα-
dystrophin, which constitutes the molecular biological basis
for laminin’s participation in cell-matrix interactions [22].
4.3. Nidogen and Proteinuria. Nidogen, also known as
entactin, is a single-stranded glycosidoprotein of 150kDa in
molecular weight. It was originally extracted from the extra-
cellular matrix of an Engelbreth-Holm-Swarm (EHS) tumor.
Nidogenconsistsofthreesphericalregions(G1,G2,andG3),
and region G3 associates noncovalently with the γ1c h a i no f
laminin in an equimolar fashion. Region G2 associates with
collagen type IV in a manner similar to how the collagen
stromaislinkedwiththelamininmeshwork.Thisregionalso
binds to basement membrane proteoglycans. Therefore,
through its ability to crosslink other GBM components,
nidogen plays an important role in the development and
maintenance of GBM integrity.
4.4. Heparan Sulfate and Proteinuria. Proteoglycans on the
GBM are dominated by heparan sulfate(HS) polysaccharide.
This includes proteoglycans such as perlecan and agrin,
which are distributed in the GBM. Heparan sulfate is rich
in negative charges that can limit the ability of negatively
charged plasma proteins to pass. It is therefore an important
participant in the glomerular charge barrier. HS may also
interact with collagen and laminin in the GBM to maintain
the structural integrity of GBM molecules. It may therefore
also exert an eﬀect as a mechanical barrier [23]. It has
been found in animal experiments that one-oﬀ intravenous
injection of HS monoclonal antibodies or digestion of HS
with heparinase in rats may both induce massive proteinuria
in rats. Data from perlecan N-terminal gene-knockout mice
has shown that there are no obvious morphological changes
to the kidneys of these mice under physiological conditions,
but their kidneys are highly sensitive to protein load. When
injecting bovine serum albumin into these mice, massive
proteinuria emerges [23]. In addition, studies on agrin show
that it may promote the anions binding to the GBM. These
studies show that perlecan and agrin play important roles in
maintaining theGBM chargebarrier and mechanicalbarrier.
5. PodocytesandProteinuria
In podocytes and podocytic processes, SDs are important
components of the glomerular ﬁltration barrier. Slit dia-
phragms are zipper-like membranaceous electrodense struc-
tures that are linked in a zigzag fashion among podocytic
processes. Most studies show that SDs have a rigid structure
with a relatively constant diameter (20–50nm) and are com-
posed of multiple protein complexes. The bridging adjacent
podocytic processes are the last barriers of glomerular ﬁltra-
tion. The slit membrane can be divided into three parts: an
extracellularpart(theextracellularportionofthetransmem-
brane protein on the slit membrane), a transmembrane part
(the intramembrane part of the transmembrane protein and
the membrane-associated protein on the podocytic mem-
brane), and an intracellular part (the cytoplasmic domain
of the transmembrane protein, and other membrane-related
proteinsandslitmembraneproteinsinpodocyte).Anumber
of SD molecules expressed by podocytes have recently been
discovered and can be classiﬁed into four categories: SD
membrane proteins including Nephrin, podocyte skelemins
including α-actinin-4, basement membrane-podocyte
junctional membrane proteins including α3β1 integrin and
podocyte terminal membrane proteins including Podoca-
lyxin [24]. In depth study of the structural molecules of4 International Journal of Nephrology
podocytes may accelerate further understanding of the
structure and function of the glomerular ﬁltration barrier
and may clarify the pathogenesis of proteinuria.
5.1. Nephrin and Proteinuria. Nephrin was the ﬁrst SD
molecule found in podocytes. It is the transmembrane pro-
tein encoded by the NPHS1 gene and is composed of 1241
amino acids. It belongs to the immunoglobulin superfamily
of cell adhesion molecules and is located speciﬁcally in the
glomerular slit diaphragm region. The extracellular amino
terminal region of nephrin molecules has eight Ig repetitive
sequences, one interval region and one type III ﬁbronectin-
likeregion.EachIgmotifcontainstwocysteines(Cys),which
may form a disulﬁde bond in the Ig repetitive structure,
endowing the Ig motif with a spherical or elliptical form. If
the Ig motif forms a chain-like structure, the slit diaphragm
is the widest part of the structure (35–45nm). In addition
to the two Cys residues contained in each Ig motif, the
nephrin molecule also has three free Cys: one located in
the ﬁrst Ig motif, one in the interval region and one in the
ﬁbronectin-like region. A Cys in the ﬁrst Ig motif forms a
disulﬁde bond with another Cys in the interval region of
the nephrin molecule; the two molecules show homophilic
adhesion. In this way, many nephrin molecules form axial
ﬁlaments along the slit diaphragm. In addition, a Cys in the
ﬁbronectin-like region may form a disulﬁde bond with
another nephrin molecule or with an unknown protein con-
nectingtheslitdiaphragmandthecytoskeleton.Insummary,
the three free Cys residues participate in the formation of
intermolecular disulﬁde bonds that enhance the integrity
of the slit diaphragm. Deletion of these three Cys residues
may relax the slit diaphragm, leading to its disappearance,
disrupting the ﬁltration barrier and inducing proteinuria
[25].
A gene mutation in nephrin can lead to congenital
nephrotic syndrome of the Finnish type (CNF), with clinical
featuresincludingmassiveintrauterineproteinuria,aplacen-
tal weight exceeding the body weight by 25% at birth and
signiﬁcantedema.Thissyndromeisprogressive,andpatients
usually die within 2 years after birth. At the ﬁrst day after
intravenous injection of extracellular antinephrin mono-
clonal antibody (mAb)5-1-6 into rats, massive proteinuria
hasbeenshowntoemergeandtopeakondayﬁve.Studieson
models of nephrotoxic serum nephritis, Heymann nephritis,
and amino nucleotide nephropathy determined that the
expression of nephrin in renal structures of mice was sig-
niﬁcantly decreased in the model group. Moreover, the mice
developed massive proteinuria [25, 26].
5.2. Podocin and Proteinuria. Podocin is an integral mem-
brane protein that was detected while studying steroid-
resistant congenital nephrotic syndrome using targeted clon-
ing technology. It is encoded by the NPHS2 gene [27].
Podocin is a new member of the stomatin family of lipid
raft-associated proteins and consists of 383 amino acids with
the molecular weight of 42kDa and a “hairpin-like” single
membrane region. Its N- and C-termini are located in the
cytoplasm. Podocin interacts with nephrin and CD2AP via
its C-terminus. It plays an important role in maintaining
the structure and function of SDs as a supporting protein.
Studies in zebra ﬁsh found that at 72 and 96h after fertiliza-
tion,theexpressionofglomerularpodocinproteindecreased
or disappeared, leading to abnormalities in slit diaphragms
and preventing the formation of normal podocytic processes
[27].
NPHS2 gene-encoding podocin knockout mice showed
proteinuria prior to birth and died within several days fol-
lowing birth; their pathological manifestation was severe
mesentery sclerosis. Extensive subpodocytic fusion and slit
membrane disappearance could be observed via electron
microscopy. NPHS2 gene mutations have been detected in
syndromes such as human congenital familial steroid-
resistant nephrotic syndrome and sporadic steroid-resistant
nephrotic syndrome [28–30], suggesting that podocin plays
an important role in maintaining the structure of podocytic
processes and the integrity of slit membranes. Podocin could
be of great importance in the pathogenesis of proteinuria.
5.3. CD2AP and Proteinuria. CD2AP is a transmembrane
protein belonging to the immunoglobulin superfamily and
is composed of 639 amino acids with a molecular weight of
80kDa. It was initially determined that, as an intracellular
ligand of T cell and natural killer cell CD2 receptors, CD2AP
can stabilize connections between T cells and antigen-
presenting cells. Furthermore, CD2AP is extensively expres-
s e di nv a r i o u ss t r u c t u r e so fh u m a n sa n dm i c e ,a n di t
has been shown through immunoelectron microscopy that
CD2AP localizes near the intracellular segment of nephrin
in the podocyte side wall. Simultaneous immunoﬂuores-
cence conﬁrmed that CD2AP is primarily expressed in the
glomerulus of the kidney and located at the podocyte slit
membrane within the glomerulus and can also be detected
in the concentrated pipe as well as some proximal and distal
tubules. Its N-terminus contains a Src homology 3 (SH3)
domain that can identify the proline-rich amino acid
sequence in the intracellular C-terminus of CD2. The middle
segmentisaproline-richstructuraldomainthathasavariety
of loci and can bind with a number of enzymes and protein
molecules. The C-terminus has the binding sites for the
helical structure region and the actin cytoskeleton; the
leucine zipper domain in the C-terminus can regulate the
development of the CD2AP homodimer [31, 32]. As an
adaptin, CD2AP can interact with slit membrane proteins
such as podocin and nephrin via its C-terminus, locating its
anchor within subpodocytic lipid rafts in order to preserve
the functions of the cytoskeleton and SD. Damage to CD2AP
notonlyaﬀectsthefunctionofSDs,butalsodirectlydamages
the podocyte cytoskeleton, disrupting the stability of the
cytoskeleton and leading to pathological changes such as
subpodocyticdeformationanddisappearance,thusinducing
massive proteinuria [33]. In addition, CD2AP can interact
with various signaling molecules via its SH3 region and
participate in cytoskeletal assembly. The CD2AP gene-
knockout mouse develops subpodocytic fusion or disap-
pearance one week after birth, mesangial cell proliferation,
extracellular matrix deposition and proteinuria at week two,
and nephrotic syndrome at weeks three or four and dies
of proteinuria and renal failure as a result of subpodocyticInternational Journal of Nephrology 5
defects at weeks six or seven. This indicates that CD2AP is of
great importance for maintaining the structure of podocytes
and SDs [31, 32]. Nevertheless, no nephrin abnormalities
were detected in this model at the genetic level or with
respecttoproteinlocalization,suggestingthattheinteraction
betweenCD2APandnephrin is notnecessaryforthegenera-
tion and aggregation of nephrin. Only when severe glomeru-
lar injury occurs can changes be observed in nephrin, which
might be related to the disappearance of the subpodocytic
slit diaphragm. Another study showed that nephrin was
expressed earlier than CD2AP and that CD2AP gene-
knockout mice showed a gradual disappearance of podocytic
processes that were previously normal in appearance. These
ﬁndingssuggestthatnephrincaninducepodocytic processes
independent of CD2AP, but CD2AP is of great signiﬁcance
for maintenance of the morphology and function of the
subpodocytic slit diaphragm [26].
5.4. NEPH1 and Proteinuria. NEPH1 is a transmembrane
protein with a molecular weight of 110kDa. The human
Neph1 gene is located in chromosome 1 (1g21-q25), within
a known gene domain relating to childhood nephrotic
syn-drome. The NEPH family contains three members:
NEPH1, NEPH2, and NEPH3. They all belong to the immu-
noglobulin superfamily and have ﬁve similar extracellular
immunoglobulin-likerepetitivesequences,atransmembrane
region and an intracellular region composed of 198–235
amino acids. NEPH1 is extensively distributed in many tis-
sues of humans and mice; its expression level is highest in the
kidney. Immunohistochemical staining has shown that the
molecule is only expressed in podocytes and immunoelec-
tron microscopy conﬁrmed that the molecule is localized to
the slit membrane [34, 35]. Neph1 knockout mice demon-
strated similar phenotypes to nephrin knockout mice. At
1 week after birth, they were weaker and smaller than
normal mice and without edema; however, with the devel-
opment of the disease, almost all of the mice developed pro-
teinuria to varying degrees and died 3-4 weeks after birth.
Electron microscopy showed the existence of subpodocytic
fusion,suggestingasigniﬁcantroleforNeph1inmaintaining
the integrity of the glomerular ﬁltration barrier [36].
Nephrin and NEPH1 gene deletions can lead to similar
phenomena, such as subpodocytic fusion, proteinuria, and
high perinatal mortality, suggesting that they may have
the same pathological mechanism. Immunocoprecipitation
showedthattheextracellularsegmentofnephrincaninteract
convergently and divergently with the extracellular region of
NEPH1 and its own extracellular region, respectively, but
that NEPH1 does not interact with its own extracellular
region. This indicates that nephrin and NEPH1 form a kind
of heterogeneous oligomer receptor complex on the sub-
podocytic slit diaphragm by cis-trans interactions which
participates in the formation of the SD zipper-like structure
and maintains the normal structure of podocytes and the
integrity of SDs. This interaction is rather complex and
involves multiple immunoglobulin-like structural domains
of the two molecules [35, 37].
Podocin has a tissue distribution similar to that of the
NEPH family. Immunocoprecipitation showed that the
intracellular regions of the three members of the NEPH
family can all bind to the podocin C-terminus. Podocin can
also precipitate endogenous NEPH1 originating from podo-
cytes. The intracellular segments of proteins in the NEPH
familyallhaveahighlyconservedsequencecomposedofnine
amino acids (KDPTNGYYxV). NEPH1 gene mutation or
replacement of the no.7 tyrosine of the conserved sequence
with an alanine can block the association of NEPH1 and
podocin, conﬁrming that the integrity of this conserved
segment is of great importance for the interaction between
podocin and NEPH1. The speciﬁc mechanism of podocin
and Neph1 interaction involves dephosphorylation of tyro-
sine 637 of NEPH1 via Tec kinase, which promotes the
association of NEPHI and the podocin carbon terminus. The
interaction between NEPH1 and podocin plays a signiﬁcant
role in the maintenance of podocyte SDs [38].
5.5. α-Actinin-4 and Proteinuria. Four members of the α-
actinin family have thus far been identiﬁed: α-actinin-1
(nonmuscle type), α-actinin-2 (muscle type), α-actinin-3
(muscle type), and α-actinin-4 (nonmuscle type). Only α-
actinin-4 expression has been found in renal tissues, primar-
ily in podocytes, and its coding gene, ACTN4, is located on
chromosome 19q13. α-actinin-4 is an actin ﬁlament cross-
linked protein with a molecular weight of approximately
100kDa, and it is an antiparallel homodimer and is dumb-
bell-shaped (width: 4-5nm, length: 40–50nm). It consists
of three structural domains: the N-terminal CH domain is
an actin binding domain (ABD) containing 250 amino acid
residues. The C-terminal 150 amino acid residues constitute
the CaM domain, containing two “EF hand” repeats. The
central α-helix repetitive fragment is comprised of the four
spectrinr epeatsfr omR1-R4,eachfragmentc onsistingof122
amino acid residues forming a rod-like structural domain.
Podocyte α-actinin-4 is formed through interaction between
the two identical peptide chains via the central spectrins. α-
actinin-4 can regulate actin polymerization and depolymer-
ization.Itbundlesthelooseactinﬁbersinpodocytesintofas-
ciculi with contraction through the ABD structural domain
on both ends in order to stabilize podocyte cytoskeletal
structures such as actin and actin ﬁlaments, maintain the
morphology of podocytic processes, and regulate the move-
ment of the cytoskeleton [39, 40]. α-actinin-4 is extensively
expressedinpodocytes.Inexperimentalnephroticsyndrome
as well as primary and secondary human glomerular lesions,
α-actinin-4isexpressedandabnormallylocalized,alongwith
abnormal expression of other SD-related proteins [41]. Gene
mutations in ACTN4 may lead to focal segmental glomeru-
losclerosis, suggesting that the actin cytoskeleton may aﬀect
the structure or function of podocytes and participate in
the occurrence and development of proteinuria [42]. α-
actinin-4 deletion in mice showed progressive proteinuria,
and these mice died within a few months of birth. Early
electron microscopy results showed regional subpodocytic
fusion which later became diﬀuse fusion, and indicated that
the structure of the SDs was severely disrupted [43]. These
results indicate that α-actinin-4 is of crucial importance for
the maintenance of cytoskeleton and SD functions.6 International Journal of Nephrology
5.6. α3β1 Integrin and Proteinuria. Integrins are a class of
molecules belonging to the transmembrane glycosidoprotein
cell surface receptor family and are heterodimers formed by
α and β subunits through noncovalent bonds. To date, 16 α
subunits and nine β subunits have been identiﬁed, which
together assemble into at least 19 kinds of integrins. Accord-
ing to diﬀerences in β subunits, the integrin family can be
divided into three subfamilies: β1, β2, and β3. The kidneys
are dominated by the β1 subfamily, including α3β1 integrin
and others. In kidneys, α3β1 integrin is highly expressed
in podocytic processes along the glomerular basement
membrane, and the molecules exist extracellularly in the
form of membrane proteins and contain a transmembrane
region and an intracellular region. The α3 subunit has the
molecular weight of 150kDa and is encoded by the ITGA3
gene located on chromosome 17. It has been found that
this subunit contains a site for binding calcium ions. The
β1 subunit has four Cys-rich repeats whose macrocycles
at the terminal extracellular amino acids are reinforced by
intrachain disulﬁde bonds (S-S). There is also an integrin-
linked kinase (ILK) on this subunit. When podocytes are
injured, the activated ILK phosphorylates the intracellular
region of the β1 subunit, thereby reducing the binding
between α3β1 integrin and the basement membrane. The
globular regions at the terminal amino acids of the integrin
α3a n dβ1 subunits interact with each other, forming the
extracellularligand-bindingsite,andbindwiththebasement
membrane laminin, collagen IV and ﬁbronectin at focal
contacts.Thecytoplasmicdomainsofthetwosubunits,how-
ever, are comparatively shorter and bind with subpodocytic
cytoskeletal secondary ﬁlaments mediated by actin auxiliary
protein molecules such as Talin, Vinculin, and Paxillin.
The formed “basement membrane-integrin-cytoskeleton”
structure not only stabilizes the podocyte cytoskeleton, but
also initiates the integrin-dependent signaling pathway as a
transmembrane information system. This aﬀects cell mor-
phology and the cell cycle, regulates gene expression and
cytoskeletal assembly and contraction, and modulates cell
proliferation, diﬀerentiation, and apoptosis [44, 45]. Animal
experiments showed that anti-α3β1 integrin antibodies
can separate podocytic processes from the GBM and induce
proteinuria. In human FSGS patients and in puromycin-
aminonucleoside- (PAN-) induced nephropathy mouse
models, there were signiﬁcantly downregulation of α3β1
integrin expression than in the normal control group. More-
over, their expressions were clearly decreased prior to the
morphological changes in the podocytes. It is therefore clear
that α3β1 plays an important role in maintaining the normal
morphology and functioning of podocytes [46].
5.7. TRPC6 and Proteinuria. Transient Receptor Potential
Cation channel 6 (TRPC6) is a hexametric transmembrane
protein with intracellular N- and C-termini and a pen-
tameric and hexametic transmembrane structure constitut-
ing a nonselective cation channel. The TRPC family can be
divided into four subgroups according to structural homol-
ogy and functional speciﬁcity: TRPC1, TRPC2, TRPC4/5,
and TRPC3/6/7. A large number of TRPC6 proteins are dis-
tributed in brain tissues, with some in the lung and ovary. In
the vascular system, TRPC6 is distributed in smooth muscle
cells and endothelial cells and participates in the regulation
of vascular smooth muscle function. TRPC6 is expressed in
the glomerulus and renal tubules, but is primarily localized
in podocytes. Immunogold labeling has shown that TRPC6
is located in primary and secondary podocytic processes,
especially around the SD annex. Immunoﬂuorescence dou-
ble labeling showed that podocyte TRPC6 is colocalized with
Nephrin, Podocin, and CD2AP, and immunoprecipitation
showed that TRPC6 interacted with Nephrin and Podocin,
but not with CD2AP [47, 48].
TRPC6 knockout mice primarily exhibited an elevation
in blood pressure and increased arterial ring contraction
induced by the agonist, indicating that TRPC6 plays a rather
important role in regulating vascular smooth muscle func-
tion [49]. A TRPC6 gene mutation may cause familial FSGS,
as the mutation detection rate of TRPC6 was 7% in familial
FSGS. A major clinical manifestation of proteinuria has also
been observed. The majority of patients develop end-stage
renal diseases about 10 years after onset, and pathological
renal manifestations are common in FSGS. Studies on
secondary FSGS found that TRPC6-originating calcium
inﬂux leads to the abnormal localization of Nephrin in
the SD, such that Nephrin is unable to function normally,
leading to changes in TRPC6-mediated calcium currents,
which are critical in the regulation of intracellular molecules
and cytoskeletal behavior in podocytes [49, 50].
5.8. Megalin/gp330 and Proteinuria. Megalin/glycosidopro-
tein (gp330) is a receptor involved in multiple-ligand-
mediated endocytosis. It is located on one side of podocytes,
as well as in microvilli of clathrin-coated fovea and proximal
convoluted tubules. It belongs to the LDL receptor family,
and its ligands include apoE-rich β-VLDL, lipoprotein (a),
lactoferrin, oprotein lipase, aprotinin, plasminogen and
others. Under normal conditions, megalin on podocytes
can bind with proteins ﬁltered from the GBM and degrade
them via endocytosis. Heymann nephritis is an experimental
model of human membranous nephropathy. In this model,
the following reactions are triggered after binding occurs
between a megalin antibody and megalin: (1) an antigen
antibody complex-activating alexin cascade, resulting in the
formation of C5b-9 membrane attack complex and exerting
cytolytic toxicity; (2) enhanced expression of subsolvent
NADPH oxidases in podocytes, which are activated and
translocatedtothecellmembrane,generatingalargenumber
of reactive oxygen species; and (3) apoE and apoB100
aggregation that is observed at sites of regional aggregation
andregionalimmunecomplexdepositionofvariousmegalin
ligands, which are all megalin ligands. apoE and apoB100
undergo peroxidizing modiﬁcations as a result of the eﬀects
of reactive oxygen species produced during the cytotoxic
process initiated by alexin. Lipid peroxidation leads to
glomerular capillary wall injury, causing proteinuria that is
clear alleviated after treatment with probucol, an inhibitor of
lipid peroxidation [51].
5.9. WT1 and Proteinuria. Another well-described genetic
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the spectrum of clinical pictures caused by mutations in
Wilms tumor suppressor gene 1 (WT1), a transcription
factor regulating the expression of many genes through DNA
binding [52]. WT1 was identiﬁed by positional cloning in
children with the WAGR syndrome, a syndrome character-
ized by the association of Wilms’ tumor (W), aniridia (A),
genitourinary malformations (G), and mental retardation
(R) [53]. The WT1 gene contains 10 exons and spans
approximately 50kb on chromosome 11. It generates a 3kb
mRNA and encodes a 52–54kDa protein [54]. In addition to
being a tumor suppressor gene, WT1 has been shown to play
crucial roles during embryogenesis, especially during kidney
development [55]. WT1 mutant mice do not form kidneys
and mice lacking the transcriptionally active WT1 splice
variant WT1-KTS develop kidneys with very few immature
glomeruli [56]. The WT1 gene is widely expressed in epithe-
lial cells of early nephron and is restricted to podocytes in
the mature glomeruli [57]. Based on this, WT1 is often
utilized as a molecular marker for evaluating podocyte num-
ber and density under diﬀerent circumstances [58]. Several
lines of evidence suggest that WT1 may indeed play an
important role in the maintenance of normal podocyte
function [55]. Heterozygous de novo mutations in WT1
cause Denys-Drash syndrome (DDS) and Frasier syndrome
(FS) [59]. WT1 is mutated in 94% of all Denys-Drash syn-
drome (DDS) patients, companied with the development of
glomerular nephropathy involving glomerulosclerosis [55].
WT1 mutations have also been found in patients with
nephrotic syndrome and isolated cases of glomerulosclerosis
[57, 60]. In addition, WT1 is downregulated in a variety of
glomerular diseases with podocyte injury, and WT1 mRNA
is detected in the urine of some patients with glomerular
diseases [61]. WT1 plays a fundamental role in controlling
the expression of major podocyte-speciﬁc genes such as
nephrin and podocalyxin in adult kidney [62, 63]. Although
it has been implicated that changes in the expression of TGF-
β1, PDGF-α, and Pax-2 which are regulated by WT1 aﬀect
cytoskeletal architecture [64], the complete set of WT1’s
targets in podocytes remains to be deﬁned.
5.10. PLCE1 and Proteinuria. PLCE1 (phospholipase C
epsilon-1) gene locates at chromosome 10q23.32-q24.1, and
its encoded protein-phospholipase Cε1( P L C ε1) is a member
of phospholipase C (PLC) family [65]. PLCε1i sap h o s -
pholipase enzyme that catalyzes the hydrolysis of phos-
phatidylinositol-4,5-bisphosphate and generates two second
messengers: inositol 1,4,5-triphosphate (IP3) and diacylglyc-
erol (DAG), which then initiate a cascade of intracellular
responses that result in diﬀerential gene expression, cell
growth, and diﬀerentiation [58]. PLCε1 expresses in the
matured podocyte of renal glomerulus and plays an essential
role in the formation and normal development of capillary
loop of glomerulus [65] .T h er o l eo fP L C E 1i nr e n a lp a t h o -
physiologyremainscomplicated.MutationsinPLCE1,which
wasidentiﬁedasanewcauseofautosomalrecessivenephritic
syndrome in children that present with diﬀuse mesangial
sclerosis (DMS) and FSGS, cause arrest of glomerular podo-
cyte development at the S-shaped stage, thereby halting
glomerular development and causing nephrotic syndrome
[65, 66]. But enhanced signalling through a form of PLC
within podocytes results in podocyte injury and proteinuria
[67]. It has been shown that PLCε1 interacted with H-Ras,
IQGAP1 (IQ motif-containing GTPase-activating protein 1)
and BRAF (v-raf murine sarcoma viral oncogene homolog
B1), then serving as crucial intermediates in many signaling
pathways [68]. Identiﬁcation of additional proteins that are
expressed in the podocyte and interact directly or indirectly
with PLCε1 will be needed to help in the understanding of
how mutations in PLCE1 cause nephrotic syndrome.
5.11. Lmx1b and Proteinuria. Lmx1b is one of a family of
more than nine LIM-homeodomain genes regulating gene
transcription via its interactions with gene promoter and
enhancer sequences, in conjunction with other transcription
factors [69]. Mutations in Lmx1b cause nail-patella syn-
drome (NPS), an autosomal dominant disease with skeletal
abnormalities, nail hypoplasia, and nephropathy [70]. Renal
involvement occurs in 25% to 60% of cases, ranging from
nonnephrotic proteinuria to end-stage renal disease [71].
Ultrastructurally, foot process eﬀacement was observed for
a certain percentage of podocytes [72]. It has been reported
t h a tL m x 1 bi sr e q u i r e df o rn o r m a lp o d o c y t ed i ﬀerentiation
[73]. Lmx1b −/− mice exhibit kidney defects as well as
patterning defects in appendicular skeletal structures and
associated soft tissues, and they die shortly after birth [74].
It has been demonstrated that the transcription of podocin
is mainly regulated by the transcription factor Lmx1b, which
binds to a FLAT-F element and displays enhancer function
[75]. However, a study of a podocyte-speciﬁc Lmx1b knock-
out showed later development of proteinuria and greater
expression of type IV collagen chains and podocin [76].
5.12. SMARCAL and Proteinuria. Mutations in SMAR-
CAL1 (SWI/SNF-related, matrix-associated, actindependent
regulator of chromatin, subfamily a-like 1) are involved
in the development of Schimke immunoosseous dysplasia
(SIOD).Thisautosomalrecessivedisorderischaracterizedby
the autosomal recessive transmission of spondyloepiphyseal
dysplasia and characteristic dysmorphic features, lympho-
cytopenia and/or T-cell immunodeﬁciency, and renal dys-
function including proteinuria and nephrotic syndrome due
to FSGS [77]. Two families have been reported in which
siblingsofaﬀectedindividualshaveincompletepenetranceof
SIOD [78, 79]. Furthermore, mutations in SMARCAL1 were
also found in two siblings with an incomplete phenotype
of SIOD. The siblings were initially classiﬁed as suﬀering
from familial steroid-resistant nephrotic syndrome [80]. As
SMARCAL1 encodes a SWI/SF2-related protein involved
in chromatin remodeling [81], it is tempting to speculate
that SMARCAL1 regulates expression of podocyte proteins.
However,podocytegenespotentiallyregulatedbySMARCAL
remain to be identiﬁed.
5.13. MYH9 and Proteinuria. An exceptional example of the
genetic complexity of nephrotic syndrome was shown by
two independent studies demonstrating a strong association
of common genetic variants in the MYH9 gene with
FSGS and hypertensive ESKD [82, 83]. MYH9 encodes for8 International Journal of Nephrology
the heavy chain of nonmuscle myosinIIA (NMMHC-IIA).
MYH9 is abundantly expressed in glomeruli, and mainly in
podocytes [84]. It has been reported that NMMHC-A acts as
a component of the podocyte cytoskeleton, contributing to
its contractile functions [85]. A growing body of evidence
indicates that loss of MYH9 function may be suﬃcient to
cause kidney disease. Podocyte-speciﬁc deletion of MYH9
mice is predisposed to Adriamycin-induced glomerular
injury, including podocyte eﬀacement, glomerulosclerosis
and proteinuria [86]. Recently,it has been demonstrated that
podocytes host response to HIV-1 includes downregulation
of MYH9 expression, and this downregulation might play a
roleinthepathogenesisofHIVAN[87].Furthermore,MYH9
polymorphisms are associated with diabetic nephropathy
in European Americans [88]. However, the underlying
pathophysiologic events occurring at the chronic kidney
disease associated with MYH9 high-risk haplotypes remain
unknown.
5.14. SCARB2 and Proteinuria. Mutations in the lysoso-
mal membrane protein human scavenger receptor class B,
member 2 (SCARB2), have recently been found to cause
action myoclonus renal failure syndrome (AMRF) in
humans, which is characterized by collapsing FSGS and
progressive myoclonic epilepsy [89]. Clinical report of two
siblings revealed that AMRF resulted from a mutation in
the SCARB2 gene and the renal involvement was due to
nephropathy C1q [90]. SCARB2 (Limp-2 in mice) encodes
for the ubiquitously expressed lysosomal integral membrane
protein type 2 (LIMP-2) mainly found in lysosomes and late
endosomes [91]. This LIMP-2 protein has been shown to
act as a receptor to bind β-glucocerebrosidase which is a
lysosomal enzyme deﬁcient in most cases of Gaucher disease
[92]. LIMP-2 knockout mice have tubular proteinuria due to
an inability to fuse lysosomes with endosomes and degrade
reabsorbed proteins [93]. Recently, although novel SCARB2
mutation has been found in AMRF [94], the pathophys-
iologic events leading to glomerular disease in cases with
SCARB2 mutations remain unknown.
5.15. Other Podocyte-Related Molecules and Proteinuria. The
components of SDs also include many other podocyte-
related molecules, such as Densin, which binds to the
cytoskeleton to maintain the polarity of podocytes and
interacts with podocalyxin, megalin, and α-actinin-4 within
podocytes. Moreover, Densin participates in the pathogen-
esis of proteinuria. Glomerular epithelial cell protein 1
(GLEPP-1) is a newly discovered receptor-like membrane
protein tyrosine phosphatase (RPTP). In the kidney, it is
speciﬁcally expressed at the plasma membrane on top of
podocytic processes. P-cadherin plays a role in connect-
ing SD structural molecules. Galloway Mowat Syndrome
(GMS) is a rare autosomal recessive disorder comprising
of nephrotic syndrome with central nervous system invol-
vement [95]. Linkage studies in two Algerian families iden-
tiﬁed a homozygous mutation in the GMS1 gene [52].
Recent exome sequencing as well as a whole-genome linkage
analysis revealed MYO1E mutations in childhood pro-
teinuric disease and FSGS [96]. MYO1E appears to be
important for podocyte motility and may also stabilize the
podocyte cytoskeleton [97]. In addition, synaptopodin is
an actin-associated protein essential for the integrity of the
podocyte actin cytoskeleton because synaptopodin-deﬁcient
mice display impaired recovery from protamine sulfate-
induced foot process eﬀacement and lipopolysaccharide-
induced nephrotic syndrome [98]. Besides, recent studies
found that the normal expression of CD38 importantly
contributes to the diﬀerentiation and function of podocytes
and the defect of this gene expression may be a critical
mechanism inducing EMT and consequently resulting in
glomerular injury and sclerosis [99], and CD151 as a crucial
modiﬁer of integrin-mediated adhesion of podocytes to
the GBM [100]. However, the functions of these molecules
remain undeﬁned and require further study.
6. Mitochondrial DisordersandProteinuria
Mitochondrial DNA plays a crucial role in oxidative pro-
duction of energy. Thus, defects in mitochondrial DNA can
aﬀect virtually all organ systems. Mitochondrial DNA muta-
tions have been recently described also in association with
kidney disease, mainly focal and segmental glomerulosclero-
sis [101].
6.1. CoQ10 and Proteinuria. Coenzyme Q10 (CoQ10) is a
lipophilic molecule that transfers electrons from mitochon-
drial respiratory chain complexes I and II to complex III
[102]. CoQ10 deﬁciency is associated with a variety of
clinical phenotypes, including nephrotic syndrome [103].
COQ2 mutations have been identiﬁed in patients present-
ing with early-onset NS, severe oliguric renal failure and
collapsing glomerulopathy [104]. Dietary supplementation
with Q10 provides a dramatic rescue of both proteinuria and
interstitial nephritis in the interstitial nephritis mice model
[105]. Moreover, administration of CoQ10 had signiﬁcant
beneﬁcial eﬀects on albuminuria in the experimental model
of type 2 diabetes, db/db mice [106]. Recently, CoQ10
prevented altered mitochondrial function and morphology,
glomerular hyperﬁltration and proteinuria in db/db mice,
highlighting the role of mitochondria in the pathogenesis
of diabetic nephropathy and the beneﬁts of preventing
increased oxidative stress [107].
6.2. tRNA Mutation and Proteinuria. The point mutations
in the transfer tRNA Leu(UUR) gene are mainly associated
with the mitochondrial encephalomyopathy, lactacidosis and
stroke-like episode (MELAS) syndrome [108]. An A to G
transition at nucleotide position 3243 in the mitochondrial
tRNA Leu(UUR) gene has showed a pathogenic eﬀect in
maternally inherited diabetes and deafness and progressive
kidney disease [109]. A3243G mutation is also found in
patients with FSGS sometimes associated with maternally
inherited diabetes and/or sensorineural hearing loss [110].
In a report of a boy with A3243G mutation in the tRNA
Leu (UUR) gene, proteinuria was detected at the age of
6 years, including large amounts of low-molecular-weight
proteins such as beta(2)- and alpha1-microglobulin [111].International Journal of Nephrology 9
A3243G mutation was also found in the case of a 59-year-
old male with a personal and maternal history of diabetes
and deafness, who presented with cardiomyopathy and
kidney disease [112]. Furthermore, other mutations in
mitochondrial tRNA genes were described in patients with
mitochondrial cytopathy presenting with FSGS [113, 114].
7.CirculatingFactorsandProteinuria
7.1. Angiotensin II and Proteinuria. Angiotensin II, tradi-
tionally playing a central role as a mediator of glomerular
hemodynamic adaptation and injury, is now recognized to
exert proinﬂammatory action leading to upregulation of
chemokines, adhesion molecules, and other ﬁbrogenic
growth factors [115]. Podocytes are a direct target for angio-
tensin II—mediated injury by altered expression and distri-
bution of podocyte proteins. Rats receiving angiotensin II
by minipump developed hypertension in association with
proteinuria. Both real-time PCR and quantitative in situ
hybridization demonstrated a signiﬁcant increase in nephrin
gene expression in angiotensin II infused animals com-
pared with control animals [116]. Angiotensin II promotes
podocyte injury indirectly by increasing calcium inﬂux and
production of reactive oxygen species [117]. Angiotensin II
is also closely related to vascular endothelial cells. Under
physiological conditions, it regulates the development, mat-
uration, and permeability of endothelial cells [118]. Angio-
tensin I and angiotensin II, both exert their eﬀects via the
Tie2 receptor on endothelial cells. The function of angio-
tensin I lies in stabilizing endothelial cells and preventing
inﬂammatory responses, angiogenesis, and endothelial cell
permeability from increasing. On the other hand, angio-
tensin II primarily exerts its antiangiotensin I eﬀect via
binding to the Tie2 receptor.
7.2. VEGF and Proteinuria. Vascular endothelial growth fac-
tor (VEGF) is a 43–46kDa glycoprotein that serves as a key
survival factor for vascular endothelium [119]. Through
bindingwiththeVEGFRonendothelialcells,VEGFregulates
angiogenesis and endothelial cell permeability. In kidneys,
angiotensin I and VEGFs, secreted by podocytes, bind to the
glomerular vascular endothelial cell receptor Tie2 and
VEGFR, aﬀecting the phenotype of endothelial cells and the
function of their ﬁltration barrier. Circulating physiological
levels VEGF is important for the homeostasis of kidney
glomerulus. Blocking VEGF signal transduction by anti-
VEGF antibody or soluble receptors could lead to protein-
uria. An increase in the incidence of proteinuria has been
found in patients receiving anti-VEGF antibody treatment.
Moreover, neutralizing VEGFs during blood circulation in
mice treated with equimolar anti-VEGF antibody or VEGF
receptor may induce proteinuria. At this time point, the
major lesion is located in endothelial cells, manifested as
vacuolar degeneration of endothelial cells and detachment
from GBM. These results suggest that VEGFs may play a
signiﬁcant role in the pathogenesis of proteinuria [120].
7.3. Other Circulating Factors and Proteinuria. Fibroblast
growth factor 21 (FGF21) is a hepatic hormone involved in
the regulation of lipid and carbohydrate metabolism. Plasma
FGF21 levels are signiﬁcantly increased with the develop-
ment of early- to end-stage CKD and are independently
associated with renal function and adverse lipid proﬁles in
Chinese population [121].Furthermore,it hasbeen reported
that serum soluble urokinase receptor (suPAR), which is ele-
vatedintwo-thirdsofsubjectswithprimaryFSGS,maycause
FSGS [122]. A recent study investigated in 48 stage-2-to-4
CKD patients showed that circulating endogenous inhibitor
of NO synthase asymmetric dimethylarginine (ADMA)
emerged as an independent correlate of proteinuria [123].
Previous study from our group found the mineralocorticoid
aldosterone infusion in mice could induce urinary protein
excretion and podocyte injury [124]. Although increasing
evidence determined that circulating factors played a role
in proteinuria, the precise nature of these factors and the
mechanisms by which they cause renal injury need further
studies.
8.SignalingPathways andProteinuria
8.1. mTOR Signaling and Proteinuria. Mammalian target of
rapamycin (mTOR) is a highly conserved serine/threonine
kinase, which controls cell growth and metabolism in
response to nutrients, growth factors, cellular energy, and
stress. mTOR inhibitors rapamycin clinically used for immu-
nosuppression after organ transplantation can cause renal
deterioration and proteinuria after conversion from cal-
cineurin inhibitors [125]. mTOR is a widely expressed pro-
tein that mediates its functions in two complexes, mTOR
complex 1 (mTORC1) and mTORC2 [126]. Podocyte- spe-
ciﬁcmTORC1activationindiabeticmicerecapitulatedmany
diabeticnephropathyfeatures,includingpodocyteloss,GBM
thickening, mesangial expansion, and proteinuria in addi-
tion to podocyte loss [127]. Although mTOR activity was
increased in both human and animal kidneys with dia-
betic nephropathy, genetic deletion of mTORC1 in mouse
podocytes induced proteinuria and progressive glomeru-
losclerosis. Furthermore, simultaneous deletion of both
mTORC1 and mTORC2 from mouse podocytes aggravated
the glomerular lesions. These results revealed the require-
ment for tightly balanced mTOR activity in podocyte home-
ostasis [128]. Therefore, it is important to test if reduction
of podocyte mTOR activity can be harnessed as a potential
therapeutic strategy to treat diabetic nephropathy [129].
8.2. Calcium Signaling and Proteinuria. Calcium ions are
important mediators of cellular homeostasis owing to their
ability to elicit a dynamic, transient, and tightly regulated
range of biochemical responses [130]. The increase of the
cytosolic Ca2+ activity may be an early event in the patho-
genesisofprotaminesulfate-mediatedretractionofpodocyte
footprocesses[131].Previousstudieshadestablishedaninti-
mate association between Ca2+ inﬂux and the activation of
the Rho GTPases, which are cytoskeleton master regulators
[132]. Recent study showed that Rho A played an important
role in maintaining the integrity of the glomerular ﬁltration
barrier under basal conditions, but enhancement of Rho
A activity above basal levels promoted podocyte injury10 International Journal of Nephrology
[133]. Moreover, activation of the Ca2+-dependent phos-
phatase calcineurin leads to cathepsinL-mediated cleavage
of synaptopodin and to proteinuria. The calcineurin inhib-
itor cyclosporine A (CsA) blocks the calcineurin-mediated
dephosphorylationofsynaptopodinandprotectssynaptopo-
din from cathepsin L-mediated degradation [134]. Recently,
inhibition of calcium channels and chelation of extracellular
calcium reduced protamine sulfate-induced foot process
eﬀacement and albumin leakage in rat model, and cal-
cineurininhibitorsandthecathepsinLinhibitorallinhibited
protamine sulfate-mediated barrier changes. All these results
suggested calcium signaling played a critical role in the initial
stages of glomerular injury and calcium signaling might act
through calcineurin- and cathepsin L-dependent manner
[135].
9. Conclusion
Renal proteinuria is a manifestation of glomerular ﬁltration
barrier dysfunction. It is currently under debate as to which
layer of the glomerular ﬁltration barrier plays the most
important role in the pathogenesis of proteinuria. Moreover,
the functions of some SD molecules remain to be elucidated.
T h es t u d i e sd e s c r i b e dh e r e ,h o w e v e r ,p r o v i d ec l u e sf o rf u t u r e
investigations into the pathogenesis of proteinuria, paving
the way for and providing new ways think about treatment
options for patients with proteinuria-related diseases.
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